Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Original) A kit for the treatment of mammalian cancer or hyperproliferative cells, said kit comprising:

a first container comprising a tumor suppressor protein or nucleic acid selected from the group consisting of wild-type p53 protein or nucleic acid, or a retinoblastoma (RB) protein or nucleic acid; and

a second container comprising at least one adjunctive anti-cancer agent.

2. (Original) The kit of claim 1, wherein said tumor suppressor nucleic acid encodes a wild-type p53 protein.

3. (Original) The kit of claim 1, wherein said adjunctive anti-cancer agent is paclitaxel or a paclitaxel derivative.

4. (Original) The kit of claim 1, further comprising instructions describing the administration of both said tumor suppressor protein or nucleic acid and said adjunctive anti-cancer agent to inhibit the growth or proliferation of said cell.

5. (Original) The kit of claim 1, wherein said tumor suppressor protein or tumor suppressor nucleic acid is selected from the group consisting of p53, $p110^{RB}$, and $p56^{RB}$.

6. (Original) The kit of claim 1, wherein said first container contains a nucleic acid that is contained in a recombinant adenoviral vector.

7. (Original) The kit of claim 6, wherein said nucleic acid is contained in a recombinant adenoviral vector comprising a partial or total deletion of a protein IX DNA and comprising a nucleic acid encoding a p53 protein.

8. (Original) The kit of claim 7, wherein said deletion of the protein IX gene sequence extends from about 3500 bp for the 5' viral termini to about 4000 bp from the 5' viral termini.

9. (Original) The kit of claim 8, further comprising a deletion of DNA sequence designated E1a and E1b.

10. (Original) The kit of claim 6, wherein said recombinant adenoviral vector comprises the adenovirus type 2 major late promoter or the human CMV promoter, the adenovirus type 2 tripartite leader cDNA and a human p53 cDNA.

11. (Original) The kit of claim 6, wherein said vector is A/C/N/53.

12. (Original) A pharmacological composition comprising a tumor suppressor protein or a tumor suppressor nucleic acid and at least one adjunctive anti-cancer agent.

13. (Original) The composition of claim 12, wherein said adjunctive anti-cancer agent is paclitaxel or a paclitaxel derivative.

14. (Original) The composition of claim 12, wherein said tumor suppressor protein or tumor suppressor nucleic acid is selected from the group consisting of a nucleic acid that encodes a wild-type p53 protein, a nucleic acid that encodes a retinoblastoma (RB) protein, a wild-type p53 protein, and a retinoblastoma (RB) protein.

15. (Original) The composition of claim 12, wherein said nucleic acid encodes a wild-type p53 protein.

16. (Original) The composition of claim 12, wherein said nucleic acid encodes a said retinoblastoma $p110^{RB}$ or a $p56^{RB}$.

17. (Original) The composition of claim 12, wherein said nucleic acid is contained in recombinant adenoviral vector.

18. (Original) The composition of claim 17, wherein said nucleic acid is contained in a recombinant adenoviral vector comprising a partial or total deletion of a protein IX DNA and comprising a nucleic acid encoding a P53 protein.

19. (Original) The composition of claim 18, wherein said deletion of the protein IX gene sequence extends from about 3500 bp for the 5' viral termini to about 4000 bp from the 5' viral termini.

20. (Original) The composition of claim 19, further comprising a deletion of DNA sequence designated E1a and E1b.

21. (Original) The composition of claim 17, wherein said recombinant adenoviral vector comprises the adenovirus type 2 major late promoter or the human CMV promoter, the adenovirus type 2 tripartite leader cDNA and a human p53 cDNA.

22. (Original) The composition of claim 17, wherein said vector is A/C/N/53.

23. (Original) The composition of claim 13, wherein said paclitaxel or paclitaxel derivative is paclitaxel.

24. (Original) A composition comprising a mammalian cancer or hyperproliferative cell, wherein said cell contains an exogenous a tumor suppressor nucleic acid or a tumor suppressor protein and paclitaxel or a paclitaxel derivative.

25. (Original) The composition of claim 24, wherein said tumor suppressor nucleic acid is a nucleic acid that encodes a tumor suppressor protein selected from the group consisting of wild-type p53 protein, and a retinoblastoma (RB) protein.

26. (Original) The composition of claim 24, wherein said tumor suppressor nucleic acid encodes a wild-type p53 protein.

27. (Original) The composition of claim 25, wherein said retinoblastoma protein is a $p110^{RB}$ or a $p56^{RB}$.

28. (Original) The composition of claim 24, wherein said cells are a present in a mammal.

29. (Original) The composition of claim 24, wherein said cells are neoplastic cells.

30. (Original) The composition of claim 29, wherein said neoplastic cells comprise a cancer selected from the group consisting of an ovarian cancer, pancreatic cancer, a non-small cell lung cancer, small cell lung cancer, hepatocarcinoma, melanoma, retinoblastoma, breast tumor, colorectal carcinoma, leukemia, lymphoma, brain tumor, cervical carcinoma, sarcoma, prostate tumor, bladder tumor, tumor of the reticuloendothelial tissues, Wilm's tumor, astrocytoma, glioblastoma, neuroblastoma, osteosarcoma, renal cancer, and head and neck cancer.